DRY POWDER INHALER; SPECIAL EMPHASIS TO FORMULATION, DEVICES, CHARACTERIZATION & PROCESS VALIDATION PROTOCOL: A REVIEW
The therapy was carried out by inhalation of medicinal plants to cure illness of respiratory tract by ancient people. A wide range of dry powder inhaler devices are presently available on the market to convey drugs into lungs with a view to capitalize on drug delivery with low variability. Drug powder inhalers also face copious clinical challenges, particularly related to capricious patient factors such as age, clinical condition and inspiratory flow. Due to the drug formulation and the design of devices, different drug powder inhalers do not demonstrate the same performance and manufacturers are taking an assortment of device design approaches. The characteristics of an ideal drug powder inhaler, current innovations in powder formulation and device design are not unanimously unswerving in terms of dose variability, clinical efficacy, user friendliness and economy. Particle Size of active pharmaceutical ingredient must be present in size range about 1-10 Î¼m which also assurance that the patient gets the same dose every time at dissimilar airflow rate. Drug powder inhaler are formulated using four types of formulation strategies such as; Carrier free, Drug carrier, Drug additive, Drug carrier additive. Lung deposition study is accomplished by â€˜Twin Stage Impingnerâ€™. The interior breath gadget is vital in accomplishing adequate transference of breathed in medication to lung which fundamentally grouped in view of measurements sort into single-unit and multi-dosage stores.
Keywords: Drug Delivery, Nebulizer, Twinstage Impingner, Respirable particle
2. Coates MS, Fletcher DF, Chan H-K, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. Journal of Pharmaceutical Sciences. 2004; 93(11):2863-2876.
3. Adi S, Tong Z, Chan H-K, Yang R, Yu A. Impact angles as an alternative way to improve aerosolisation of powders for inhalation? European Journal of Pharmaceutical Sciences. 2010; 41(2):320-327.
4. Islam N and Gladki E. Dry Powder Inhalers (DPIs): A review of device reliability and innovation. Int. J. Pharm. 2008; 360:1-11.
5. Swarbrick J, Boylan C. J. Encyclopedia of pharmaceutical technology. New York: Marcel Dekker; Vol .20. 123-126.
6. Coates MS, Chan H-K, Fletcher DF, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. Journal of Pharmaceutical Sciences. 2009; 95(6):1382-1392.
7. Chan H-K, Young PM, Traini D, Coates M. Dry powder inhalers: challenges and goals for next generation therapies. Pharmaceutical technology erupoe. 2007; 19-24.
8. Oyarzun Ampeuri FA, Brea J, Loza MI, Torres D, Alonso MJ. Chitosan hyaluronic acid nanoparticles loaded with heparin for the treatment of asthma. Int. J. Pharm. 2009; 381(2):122-129.
9. Frijlink HW, de Boer AH. Trends in the technology-driven development of new inhalation devices. Drug Discovery Today: Technologies 2005; 2(1):47-57.
10. Hoppentocht M, Hagedoorn P, Frijlink HW, de Boer AH. Technological and practical challenges of dry powder inhalers and formulations. Advanced Drug Delivery Reviews. 2014; 75:18-31.
11. Young PM, Traini D, Edge S. Advances in pulmonary therapy. In Williams III R.o., Taft D.R., McConville J.T. Advanced drug formulation design to optimize therapeutics outcomes. Informa healthcare. 2008; 72:2-8.
12. Malcolmson RJ, Buckton G, darcy P, Cox RL, RenwichCE, Embleton JK; In byron PR, Dalby RN and Farr SJ. Respiratory Drug Delivery VI, Interpharm press IL.1998, 365.
13. Yadav N and Lohani A. Dry powders inhalers: A review. Indo global journal of pharmaceutical sciences. 2013; 3(2):142-155.
14. Maa YF, Prestrelksi SJ. Biopharmaceutical powders: particle formation and formulation consideration. Current pharm biotech. 2000; 1(282-302):1389-2010.
15. Pandita R, Rana AC, Seth N, Bala R. Process validation of dry powder inhalers: A review, International research journal of pharmacy. 2011; 2(12):114-116.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).